In the first half of 2002, Hong Kong was still mired in a lingering deflationary environment, thus hampering progress to economic recovery, with interest rates remaining depressed. For the six months ended 30th June, 2002, the Group's operation as a whole maintained satisfactory. Being affected by such factors as a reduction in interest income and a slippage of its automotive parts business due to market adjustment, the Group's unaudited net profit amounted to approximately HK$485,280,000, representing a decrease of approximately 17.8% over the same period last year after excluding the exceptional gain derived from the spin-off listing of Shanghai Jahwa United Co., Ltd. ("Shanghai Jahwa"), and down approximately 29.7% over 2001 taking into account of the above exceptional gain. The Board has resolved to pay an interim dividend of HK15 cents per share, representing an increase of about 7% over the corresponding period last year. The application by Shanghai Bright Dairy and Food Co., Ltd. ("Bright Dairy") for listing on the PRC A Share market was approved and Bright Dairy was listed on the Shanghai Stock Exchange on 28th August, 2002. Due to this, the Group will record an exceptional gain of approximately HK$220,000,000 in the second half of the year.

Over the years, through its strategy for transformation and leveraging on the various potential investment projects and market opportunities created by the buoyant PRC economy and, in particular, that of Shanghai, the Group has incubated successfully a number of new businesses that will make great steps to develop. In the years to come, the Group's profits will undergo significant structural changes, with profit contributions arising from new businesses set to increase gradually. By creating a quality profit composition with high growth, the Group will maintain steady growth. It will also focus on the development of businesses in the areas of infrastructure facilities, information technology, modern logistics, and medicine and bio-technology.

During the period under review, the Group successfully acquired and secured de facto control and management right of EAS International Transportation Limited ("EAS International"), which owns a nationwide modern logistics network. The total investment will amount to RMB265,000,000. EAS International will serve as the principal impetus to drive and develop the Group's modern logistics business, as well as accelerate the integration of the Group's overall logistics business. The Group will also actively seek to attract international partners in order to drive and benefit from the rapid growth of China's logistics industry. Medicine and bio-technology is one of the core businesses in which the Group is actively involved in operations and management. During the period, the Group made good progress, through merger and acquisition, in expanding the bases of its businesses in traditional Chinese medicine, high-tech medical equipment, and medicine and bio-technology.

Semiconductor Manufacturing International Corporation ("SMIC"), which commenced operation in September last year, has secured alliances with various partners in the fields of technology and capital investment. SMIC receives satisfactory sales orders and business operations are in line with the company's expectations. The company foresees tremendous market potential in the development of the global semiconductor market and, in particular, an increase in the domestic market demand for chips. Shanghai Information Investment Inc. ("SII") continued the development of its various information technology projects, and enhancing the construction of Shanghai Infoport in such areas as basic IP services, broadband information services, consumer credit information services, network credit and security services, electronic logistics services and software integration services, all of which will create a conducive environment for SII to achieve profit growth in the future.

In April 2002, the Group successfully raised a HK$1.6-billion revolving/term syndication loan at an interest rate of HIBOR plus 45 basis points in order to cope with the Group's business development strategies and practical needs. Market response to this relatively low-cost financing activity was positive. During the period, the Group actively went through integration and adjustment of the business development of its member companies, further intensifying the Group's overall business transformation. Each investment project progresses systematically and offers satisfactory returns.

(1) INFRASTRUCTURE AND MODERN LOGISTICS

Infrastructure facilities

The Yanan Elevated Road, the Inner Ring Road and the North-South Elevated Expressway are the main arteries of Shanghai's expressway network. These elevated road projects are currently one of the Group's main sources of cash flow, providing considerable, stable cash returns annually. As the investment costs of these projects have to be amortised every year, the accounting profits will slightly diminish each year. The cash returns will, however, continue to support the Group's overall business development, while also nurturing its new business developments. Net profits derived from the Group's elevated road projects for the first half of 2002 amounted to HK$354,000,000, accounting for approximately 67% of the Group's net business profit.

During the period, the Shanghai Pudong Waigaoqiao Container Terminal Phase One Project received approval from the relevant PRC government authority. Discussions with various investment partners are currently underway to finalise the detailed proposals in respect of its operation and commencement of construction, as well as the subsequent capital contribution procedures and work schedules. Waigaoqiao's container throughput is rising, with 2.89 million TEU recorded last year, representing RMB21,000,000,000 worth of cargo. The first half of 2002 saw an increase of approximately 26.3% in container throughput, with a corresponding 87.8% increase in profit compared with the same period last year. It is anticipated that the Waigaoqiao Project will bring new profitability to the Group's infrastructure business.

Modern logistics

The period under review saw fundamental progress in developments that make up the basic masterplan of the Group's modern logistics business. In addition to the newly established Shanghai Industrial Wai Lian Fa International Logistics Corporation Limited ("Shanghai Wai Lian Fa") and the Shanghai Industrial Sinotrans International Logistics Company Limited

("Shanghai Sinotrans"), in April 2002, the Group entered into an agreement to acquire a stake in the Beijing-based EAS International, and through which it further acquired in July 2002 a controlling interest in Hong Kong's CTII Worldwide Limited (now renamed EAS Worldwide Logistics Limited ("EAS Worldwide")). Together, these companies form a basic management operation platform that encompasses Beijing, Shanghai and Hong Kong, and through which the Group is gradually integrating its overall logistics business and expanding its nationwide reach in this area.

EAS International, a conglomerate with a nationwide modern logistics business network in China, is engaged in the businesses of freight forwarding, courier delivery, warehousing and logistics services. Established in 1985, EAS International was among the first group of PRC freight forwarders to be accredited by the International Air Transport Association ("IATA"). It attained its ISO9001 International Standard Quality System certification in 1999. EAS International currently has an annual air cargo and forwarding turnover of approximately 1.3 million tonnes and a marine cargo volume of approximately 140,000 TEU, representing a total turnover of approximately RMB2,000,000,000. EAS International has regional distribution centres in Beijing, Shanghai, Guangzhou, Shenzhen, Xiamen, Dalian, Wuhan and Chengdu, with close to 100 branches and offices nationwide servicing some 1,100 cities. Overseas, EAS International established 9 branches in Europe and Southeast Asia, providing an international transportation service network that covers more than 200 cities and regions worldwide.

In April 2002, the Group signed the sale and purchase agreement for its interests in EAS International. The first phase of the acquisition was completed in May and June. The Group invested RMB55,000,000 in the first phase of acquisition, representing a 25% interest in EAS International and securing de facto control and management right of the company. The agreement for the second phase of investment of RMB150,000,000 to acquire new shares was signed recently, bringing the Group's interest in EAS International to 50%. Subject to relevant PRC laws and regulations, the Group will eventually acquire an interest in EAS International of more than 60%.

In order to strengthen EAS International's global customer network, carrying capacity and profitability, the Group actively looked for strategic investors and joint venture partners during the period. In July 2002, through EAS International, the Group entered into a share subscription agreement with EAS Worldwide. A wholly-owned subsidiary of EAS International has secured a 51% interest in EAS Worldwide and became its controlling shareholder. The share subscription was completed in July and the company is already operational. The new acquisition enhances the overall competitiveness of the Group's logistics business. The Group will continue its search for quality international logistics partners and professional investors in a bid to elevate its logistics business platform to an even higher level.

Shanghai Wai Lian Fa commenced operation in October last year. Its key business processes are currently undergoing improvement and integration. In early 2002, it was actively engaged in securing customers and expanding its market share. It has also established a customer services department to enhance the development, retention and management of customers. Initial construction work on the logistics information platform has also been completed and preliminary trials have commenced. With a customer base reaching 80, its overall business has spiralled to over 33,000 tonnes of warehouse delivery, 2.4 million pieces of goods, nearly 35,000 warehouse product items and 41,300 tonnes of storage capacity recorded in the first half of 2002. The freight forwarding and import/export business also underwent a smooth expansion and revenue is gradually increasing.

Shanghai Sinotrans secured formal approval from the relevant PRC authorities in February 2002 and obtained its business license in March 2002. The company is engaged principally in the import/export freight forwarding business and is planning to tap into the base of logistics customers in the Shanghai Chemical Industry Zone. During the period under review, Shanghai Sinotrans set up a basic management system in accordance with the company's operating size and modern logistics requirements. The company started formal operations in July 2002.

(2) INFORMATION TECHNOLOGY

Since SMIC commenced trial operations in September 2001, orders flow has been satisfactory and the company has reached a production volume of 10,000 wafers per month in June this year. Currently, SMIC attracts professionals from all over the world and has a total workforce of over 2,600. SMIC's production facilities now occupy a total land area of 36 hectares following completion of the construction of the No.2 and No.3 factories. Together with its existing production facilities, SMIC owns over 35,000 sq. metres of clean room areas, making it one of the world's largest and the nation's most advanced semiconductor foundries. It has also successfully acquired 0.18-micron CMOS process certification, for which it has completed the construction of a standard design platform. The No. 2 and No. 3 factories are expected to begin operation in September 2002 with a production target of 30,000 wafers per month. SMIC is expected to achieve break-even by the fourth quarter of this year.

During the period, SMIC entered into sales contracts and formed alliances with various technology business partners, including Toshiba, Fujitsu of Japan and Chartered Semiconductor of Singapore. This year SMIC also established a long-term partnership in advanced semiconductor process technologies with Europe's leading research and development centre for microelectronics, IMEC, enabling SMIC to join most of IMEC's Industrial Affiliat Programs (IIAPs) for these technologies. This collaboration is an important part of SMIC's initiatives to participate in research and development activities at the global level, thereby positioning it for long-term technology leadership.

SII's net profit during the period was approximately RMB21,290,000, up about 43% compared with the same period last year. During the first half of 2002, SII was committed to developing its core businesses, making steady progress in its principal activities.

In the first half of 2002, Shanghai Cable Network Co., Ltd. completed the upgrade of its two-way cable television network for 40,000 subscribers. The upgrade for a total of 1.6 million subscribers will be completed by the end of 2002, covering most districts within the city's urban area. Currently, over 40,000 commercial subscribers have access to the company's "Cableplus" broadband data service. Construction of the Shanghai integrated information pipeline infrastructure by Shanghai Information Pipeline Co., Ltd. ("SIP") made good progress over the period. With the construction of the Shanghai Government's system service network, SIP has a total of over 600 km. pipelines, thus creating an integrated information pipeline network that covers all of Shanghai's major business districts. SIP also provides leased line and fiber services to China Netcom, China Unicom, China Mobile, Shanghai Cable, and other telecommunications and network operators. Sales contracts entered into during the first half of 2002 amounted to RMB80,000,000. Currently, Shanghai Credit Information Services Co., Ltd. ("CIS") has the personal credit information of about 2.8 million individuals stored in its consumer credit information databank and received more than 2,400 queries a day in June 2002. As at the end of June, CIS had received over 164,000 queries for credit reports and the number of credit reports issued rose by about 126.9% compared to the same period last year. In March 2002, the Shanghai Enterprise Credit Information System, the most comprehensive and integrated database in the city comprising 550,000 enterprises, was formally rolled out.

In the first half of 2002, Lucent Technologies, the major partner of Shanghai Optical Communications Development Co., Ltd. ("Shanghai Optical Communications") underwent a business adjustment and sold its interests in Shanghai Optical Communications' subsidiary, Lucent Technologies Shanghai Fibre Optics Co., Ltd. During the period, Shanghai Optical Communications also sold some of its assets in its subsidiary, Lucent Technologies of Shanghai, Ltd. Proceeds from the transfer of assets will be recorded in the second half of 2002. Due to business adjustment, Shanghai Optical Communications recorded a net profit of only approximately RMB4,990,000 during the period under review.

During the period, Shanghai Communication Technologies Centre ("SCTC") had recorded a net loss of approximately RMB1,260,000, which represented an improved performance, with losses narrowed by approximately RMB2,640,000, compared to the same period last year. In 2002, SCTC is dedicated to fostering the compatibility between its products and national mainstream products. Existing compatible products cover virtually all applications of MPEG-2. During the period, featured projects included the Xinwen light rail project, in collaboration with Shanghai Bell Co., Ltd., to implement the video frequency control business along Shanghai's Xinwen line, as well as the 2002 national digital TV key project, tendered jointly with SCTC's partner.

As a result of its share of SMIC's loss due to depreciation and interest expenses, the information technology business recorded a loss for the period of approximately HK$28,500,000.

(3) MEDICINE AND BIO-TECHNOLOGY

Complementing the Group's overall development strategy, the Group's medicine and bio-technology business segment comprises its Hong Kong-listed subsidiary, SIIC Medical Science and Technology (Group) Limited ("SIIC MedTech"), together with its three bio-technology development and pharmaceutical companies in Shanghai and the United States.

SIIC MedTech realised respectable growth in both turnover and net profit in the first half of 2002. Turnover amounted to approximately HK$420,000,000, representing an increase of about 23.7% over the same period in 2001. Operating profit amounted to approximately HK$88,220,000, up approximately 22.7% over the same period last year. Net profit of SIIC MedTech for the period was approximately HK$45,520,000. Excluding the exceptional gain derived from the listing of Shanghai Jahwa, SIIC MedTech recorded an approximate 5.3% growth in net profit compared to the corresponding period last year. The Group's share of SIIC MedTech's net profit was approximately HK$29,300,000, constituting approximately 5% of the Group's net business profit. In the first half of 2002, SIIC MedTech completed the acquisition of a 56%

controlling stake in Xiamen Chinese Medicine Co., Ltd. ("Xiamen Chinese Medicine") and raised its interests in E-COM Technology Co., Ltd. ("E-COM Technology"), a digital medical imaging system, to 24.35% to become its largest shareholder.

Sales of Hangzhou Qingchunbao's pharmaceutical and healthcare products grew by some 6.9% and 64.6% respectively compared with the corresponding period last year. During the period, the company was active in developing competitive pharmaceutical injection products with good market prospects, including the "Dan Shen Injection", the "Huang Qi Injection" and the "Herba Houttuyniae Injection". Sales of principal products, such as the "Shen Mai Injection", the "Dan Shen Injection", the "Huang Qi Injection" and the "Herba Houttuyniae Injection", increased by approximately 6.9%, 16.5%, 26.6% and 34.4% respectively over the same period last year. Meanwhile, sales of "Qingchunbao Anti-ageing Tablets" grew by approximately 70.4%.

SIIC MedTech also achieved breakthroughs in the acquisition of traditional Chinese medicine businesses. During the period, the company concluded an agreement with Xiamen Chinese Medicine to acquire a 56% stake in the latter. Xiamen Chinese Medicine was established over 30 years ago and primarily produces traditional Chinese medicine-based drugs and healthcare products. Currently, 40 of such Chinese medicines-based drugs are produced. Key products include "Xinhuang Tablet", "Haizhu Chuanxiding Tablet", "Liuwei Dihuang Pill" and "Shenshu Granules", all of which are sold under the "Dinglu 鼎爐" trademark.

With respect to its medicine retailing business, Hangzhou Huqingyutang Chinese Medicine Store Co., Ltd. is progressing steadily, with its branding advantages and sales network helping the sales of SIIC MedTech's products.

In areas of medical care and nursing, Guangdong Biolight Medical Technology Co. Ltd. made headway in its negotiations with GE Medical Systems Trading and Development (Shanghai) Ltd. in appointing the latter as its agent to distribute a selection of its products. A formal agreement was signed recently. The company will take advantage of the new relationship to solidify its sales and distribution network and expand its market share.

During the first half of 2002, SIIC MedTech increased its interests in E-COM Technology, whose digital imaging system has been adopted by a number of renowned hospitals, to 24.35%, becoming its largest shareholder. Operating results during the period were encouraging, with the total contracted sum going up by approximately 189% over the 2001 turnover.

In addition, the relevant agreements were signed recently for SIIC MedTech to acquire a 21.31% stake in MicroPort Medical (Shanghai) Co. Ltd. ("MicroPort") by way of capital injection and the issuance of new shares. MicroPort is engaged principally in the research, production, sale and service of high-tech medical instruments for micro wounds in China. This project will further consolidate SIIC MedTech's strategy of integrating the medical and pharmaceutical business and will lay a solid foundation for accelerated profit growth in future.

In the personal care sector, Shanghai Jahwa achieved approximately 7.4% increase in turnover over the corresponding period last year. Sales of its "Liushen" and "Herborist" series of products increased by some 13% and 50% respectively over the same period last year. "Herborist" was launched successfully in Xian, Qingdao, Nanjing and Shenzhen and there are currently seven franchised stores. In Hong Kong, marketing channels of "Herborist" were restructured and its products are now sold through the Watson's chain of drugstores.

Owing to an increase in research and development costs, and unsatisfactory sales of G-CSF products over the period, Shanghai Sunway Biotech Co., Ltd. ("Sunway Biotech") recorded a net loss of approximately RMB15,790,000 in the first half of 2002. During the period, Sunway Biotech completed Phase 2 clinical trials of H101, a Class One new medicine. Findings of the trials further demonstrated the safety and effectiveness of H101. Preparation work for Phase 3 clinical trials, which are expected to commence in September 2002, is underway. H103 is a project in which information about the antibodies for all cancers is provided to the body's immune system, triggering the self-identification and destruction of cancer cells by the immune system. Pre-clinical studies for H103 have been launched in the U.S. and Mainland China simultaneously.

Product sales by Shanghai Sunve Pharmaceutical Co., Ltd. ("Sunve Pharmaceutical") improved in the first half of 2002 compared with the same period last year, somewhat alleviating the negative effect of the State's regulations concerning the sale price of drugs. Sunve Pharmaceutical returned to profitability and recorded a net profit of approximately RMB4,750,000 during the period under review. During the same period, "Permixon" obtained State approval as a repackaged imported drug and sales were launched in Shanghai. New products such as "Levofloxacin Lactate" and "Wei Shaxin", which were developed in-house, received the Shanghai Municipal Quality New Product Second Class Award. SM2-NA and SDM passed the United States FDA's quality certification and entered the U.S. market, helping to expand the company's international market share for raw pharmaceuticals.

In the first half of 2002, Mergen Limited ("Mergen") finalised its contracts with leading bio-technology company CuraGen to provide it with microarrays supply, custom array design, production and array hybridization services. During the period, it was granted patents for two of its technologies. In March 2002, Mergen introduced a new array, containing 12,000 unique human genes, which emerged as its bestseller. New Rat ExpressChip™ (with 4,736 genes) and Mouse ExpressChip™ (with 8,552 genes) were also launched in May and July respectively. Mergen's first "bacterial array" will be presented in the near future.

Subsequent to the period under review, the Group subscribed HK$52,690,000 for about 9% of the equity interests in Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd. to enhance synergy in the Group's bio-medical research arena.

(4) CONSUMER PRODUCTS/RETAILING

Net profit arising from the Group's consumer products/retailing business for the period was approximately HK$130,600,000, an increase of about 15% over the same period last year and accounting for approximately 25% of the Group's net business profit.

Tobacco and Printing

Nanyang Brothers Tobacco Company, Limited ("Nanyang Tobacco") produced significant results during the period. Net profit was approximately HK$46,780,000, up 18.3% over the same period last year. Not only did it fulfil all economic and appraisal targets, but also the company successfully solidified its Singapore market and expanded into the new Taiwan market. Overall exports and domestic sales in the Hong Kong market were stable, with satisfactory growth in home-produced cigarettes, such as "Double Happiness". Sales of duty-free cigarettes rose about 103% over the same period last year, while sales of cigarettes under distribution in the Hong Kong market also recorded growth, with "Chunghwa", "Peony" and "Liushuiyin Lights" delivering respective increases of approximately 12.2%, 8.8% and 15.6%. The OEM cigarette "DJ Mix" will enter more new markets, in addition to South Korea and Japan.

The Wing Fat Printing Company, Limited ("Wing Fat Printing") realised stable growth in the first half of 2002, with turnover rising by approximately 29.1% over the same period last year. Net profit was approximately HK$43,000,000, representing an increase of about 16% over the corresponding period in 2001. During the period under review, Wing Fat Printing has developed a number of new tobacco packs for use by Nanyang Tobacco. Growth was also seen in tobacco pack orders from European Tobacco Inc. Subsidiaries of Wing Fat Printing in China reached their sales targets and continued to contribute to the profit of Wing Fat Printing.

Dairy

During the period under review, Bright Dairy applied to the China Securities Regulatory Commission for listing on the PRC A Share market and received approval from the Issuance Examination Commission (發行審核委員會). Bright Dairy was listed on 28th August, 2002 and has issued 150 million new RMB-denominated shares, raising net proceeds of approximately RMB950,000,000. As a result, the Group will record an exceptional gain of approximately HK$220,000,000 in the second half of the year. Subsequent to the listing of Bright Dairy, the Group's shareholding has dropped from 40% to approximately 30.8%.

Bright Dairy sustained satisfactory results for the period and realised sales revenues of approximately RMB2,300,000,000. Net profit for the period was approximately RMB95,500,000. While its major markets are located in Shanghai and Eastern China, the company will expand further into Northern and Southern China in an attempt to develop and broaden its domestic market. With the newly established Guangzhou Bright Dairy Product Co., Ltd. and the Beijing Bright Health Dairy Co., Ltd., both starting trial production in the second half of 2002, Bright Dairy's market share is set to expand and its dairy products evolve into a leading domestic brand. During the period, sales of Bright Dairy's bottled milk rose some 322% over the same period last year and Bright Dairy's technology centre developed 14 new products, among them include "Mai Feng" Fresh Milk and Breakfast Milk and "LOOK" Yoghurt drink. The company's thermostatic products are already distributed nationwide.

Retailing

Shanghai Orient Shopping Centre Ltd. ("Orient Shopping") realised a net profit of approximately RMB18,200,000 in the first half of 2002, an increase of approximately 23% over the same period last year. The company recorded satisfactory sales at its mega sale events held in early 2002 and hosted various product promotions and sales activities in the first half of the year, all of which created good marketing opportunities for the company to achieve sound economic returns.

(5) AUTOMOTIVE PARTS

The Group's automotive parts business recorded a net profit of approximately HK$42,300,000 for the first half of 2002, a drop of about 52% compared to the same period in 2001, and accounted for approximately 8% of the Group's net business profit.

Sales of Shanghai Huizhong Automotive Manufacturing Co., Ltd. rose compared to the same period last year, nonetheless, profit target was not being met due to substantial price cuts in domestically manufactured sedans. Total profit recorded for the period was approximately RMB66,850,000, a decline of some 61% over the same period last year. The first half of 2002 also saw the commencement of plant renovation/ construction work, project feasibility studies and equipment installation for the company's joint-venture projects.

Shanghai Wanzhong Automotive Components Co., Ltd. ("Shanghai Wanzhong") began production last year and generated a net profit of approximately RMB1,840,000 during the period under review. Sales revenue amounted to approximately RMB16,020,000, with 45 sets of imported equipment installed. Shanghai Wanzhong has tightened up the implementation of its heavy truck technology renovation project to consolidate its market share and, during the second half of 2002, will engage in the active development of new products to raise economic returns.

The net profit of Shanghai SIIC Transportation Electric Co., Ltd. ("SIIC Transportation") during the period was approximately RMB37,930,000, up about 56% over the same period last year. During the first half of 2002, the company focused on developing high value-added and high-tech products. SIIC Transportation is the nation's only supplier of door modulars for cars. Door modulars for three models of the Shanghai Brose (SVW/B5, PQ24 and BORA A4) and the super version for the Shanghai Delphi's SGM/GL8 accounted for some 34.9% of its overall sales. To expand its sales network, SIIC Transportation standardised its nationwide marketing and distribution strategies, enrolling 146 dealers in the first half of 2002; 133 of them made sales.

PROSPECTS

In the first half of 2002, Shanghai's economy continued its sustained growth. With the city's outstanding investment environment and development potential, the Group has been actively participating in key development projects being planned by the Shanghai Municipal Government, further expanding its business areas.

Currently, the Group's clearly defined objectives are to focus on developing its infrastructure facilities, modern logistics, information technology, medicine and bio-technology businesses, and to make more investment thereon. This enhances the acceleration of its business transformation. Based on this foundation, the Group will integrate its internal resources and streamline business reorganisation through integrating and contracting non-core businesses including by way of spin-offs for listing and internal reorganisation or transfer, all of which will help to create clear development objectives.

Meanwhile, the Group will continue to strive strenuously for a better financial structure, adopt stringent controls on operating costs and risks, and work to create sound business and economic returns. The Group will also continue to allocate resources efficiently and regulate corporate management in order to raise its standards of corporate governance and transparency in a bid to establish a competitive business platform, which will subsequently enhance integrated profitability and secure better returns for shareholders.

On behalf of the Board, I would like to take this opportunity to express my gratitude to our shareholders for their continuing support. My appreciation goes also to all our staff for their tremendous efforts and contributions.



Cai Lai Xing
Chairman

Hong Kong, 30 August 2002